ストックスクリーナーアプリを入手
1.73
1.70%
-0.03
アフターアワーズ：
1.76
0.03
+1.73%
前日終値:
$1.76
開ける：
$1.77
24時間の取引高:
624.65K
Relative Volume:
0.38
時価総額：
$99.13M
収益：
$70.00M
当期純損益:
$-43.21M
株価収益率:
-2.2826
EPS:
-0.7579
ネットキャッシュフロー:
$-34.03M
1週間 パフォーマンス:
-4.42%
1か月 パフォーマンス:
+1.17%
6か月 パフォーマンス:
-33.20%
1年 パフォーマンス:
-41.75%
1日の値動き範囲:
$1.725
$1.845
1週間の範囲:
$1.725
$1.895
52週間の値動き範囲:
$1.60
$4.94
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
名前
Black Diamond Therapeutics Inc
セクター
電話
617-417-5868
住所
245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA
Compare BDTX vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
1.73 | 100.85M | 70.00M | -43.21M | -34.03M | -0.7579 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-11-18 | 再開されました | Piper Sandler | Overweight |
| 2025-10-16 | 再開されました | Stifel | Buy |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2025-07-01 | 再開されました | Raymond James | Outperform |
| 2024-07-31 | 開始されました | Raymond James | Outperform |
| 2023-07-14 | 開始されました | Piper Sandler | Overweight |
| 2023-06-30 | アップグレード | Stifel | Hold → Buy |
| 2023-06-28 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-06-27 | アップグレード | Wedbush | Neutral → Outperform |
| 2022-03-29 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-03-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-09-30 | 開始されました | Stifel | Hold |
| 2021-01-07 | 開始されました | Wedbush | Outperform |
| 2020-11-24 | 開始されました | Berenberg | Buy |
| 2020-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-24 | 開始されました | Canaccord Genuity | Buy |
| 2020-02-24 | 開始されました | Cowen | Outperform |
| 2020-02-24 | 開始されました | JP Morgan | Overweight |
| 2020-02-24 | 開始されました | Jefferies | Buy |
すべてを表示
Black Diamond Therapeutics Inc (BDTX) 最新ニュース
Black Diamond Therapeutics (BDTX): BlackRock discloses 3.84M-share, 6.7% ownership - Stock Titan
Black Diamond Therapeutics Inc (BDTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BDTX|Black Diamond Therapeutics Inc|Price:1.760|Chg%:-0.080 - TradingKey
Black Diamond Therapeutics Inc (BDTX) Balance Sheet - TradingKey
Black Diamond Therapeutics Inc (BDTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
Black Diamond Therapeutics Inc (BDTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price & Overview - ChartMill
Black Diamond Therapeutics (BDTX) 24th Annual Needham Virtual Healthcare Conference summary - Quartr
Black Diamond Therapeutics (BDTX) Edges Higher Amid Key Support TestSeasonality Effect - dars.gov.et
BDTX Q1 2026 Earnings: Narrowed Loss Beats Estimates as Development Progress ContinuesConsensus Beat Rate - dars.gov.et
T. Rowe Price (BDTX) lists 4.03M shares, 7.0% stake in amendment - Stock Titan
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX) - Seeking Alpha
BDTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BDTX SEC FilingsBlack Diamond Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Behbahani Ali - Moomoo
Black Diamond Therapeutics touts Silevertinib lung cancer data, eyes FDA path - MSN
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Raman Prakash - Moomoo
Black Diamond Therapeutics 2026 Annual Stockholder Meeting Results and Voting Outcomes - Minichart
Form 4 Black Diamond Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
[Form 4] Black Diamond Therapeutics, Inc. Insider Trading Activity - Stock Titan
Black Diamond (BDTX) director awarded 40,000 stock options at $1.71 - Stock Titan
Black Diamond Therapeutics (BDTX) director awarded 40,000 stock options at $1.71 - Stock Titan
Director Garry Menzel granted 40,000 BDTX stock options at $1.71 strike - Stock Titan
Black Diamond (NASDAQ: BDTX) director receives 40,000 stock options at $1.71 - Stock Titan
Black Diamond Therapeutics (BDTX) awards 40,000-share option grant - Stock Titan
Black Diamond Therapeutics (BDTX) 2026 meeting backs directors, auditor and annual say-on-pay - Stock Titan
Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) added to Russell 2000 Index - marketscreener.com
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2000 Value Benchmark - marketscreener.com
Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) added to Russell 3000E Index - marketscreener.com
Enterprise value to EBITDA forward of Black Diamond Therapeutics, Inc. – NASDAQ:BDTX - TradingView
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell Small Cap Completeness Index - marketscreener.com
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2500 Value Benchmark - marketscreener.com
Black Diamond Therapeutics (BDTX) AGM 2026 Summary - Quartr
Price to sales forward of Black Diamond Therapeutics, Inc. – NASDAQ:BDTX - TradingView
Price to book forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX - TradingView
Black Diamond Therapeutics, Inc. Actuals & Estimates (NASDAQ:BDTX) - TradingView
Enterprise value to EBIT forward of Black Diamond Therapeutics, Inc. – NASDAQ:BDTX - TradingView
Price to earnings forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX - TradingView
Price to sales forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX - TradingView
Enterprise value to revenue forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX - TradingView
BDTX shares gain 11% in a week: Here's what you should know - MSN
BDTX Forecast — Price Target — Prediction for 2027 - TradingView
Black Diamond Therapeutics (BDTX) Rallies 3.11%: Testing Key Resistance at $1.74Moving Average Ribbon - DonanımHaber
Form 4 Black Diamond Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
Ali Behbahani of Black Diamond (NASDAQ: BDTX) receives 8,961-share award - Stock Titan
Black Diamond Therapeutics Inc (BDTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Black Diamond Therapeutics Inc (BDTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Black Diamond Therapeutics Inc - TradingKey
Black Diamond Therapeutics Inc (BDTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Black Diamond Therapeutics Inc (BDTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Black Diamond Therapeutics Inc (BDTX) 財務データ
収益
当期純利益
現金流量
EPS
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):